R 348

Drug Profile

R 348

Alternative Names: R 932348; R348

Latest Information Update: 28 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antirheumatics; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Keratoconjunctivitis sicca; Psoriasis; Rheumatoid arthritis; Skin disorders; Transplant rejection

Most Recent Events

  • 27 Feb 2017 Discontinued - Phase-II for Graft-versus-host disease in USA (Ophthalmic)
  • 01 Jul 2016 Rigel Pharmaceuticals completes the phase II DROPS-2 trial for Keratoconjunctivitis sicca in patients with ocular Graft-versus-host disease in USA (NCT02040623)
  • 13 Aug 2014 Discontinued - Phase-II for Keratoconjunctivitis sicca in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top